The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes
|ClinicalTrials.gov Identifier: NCT00002356|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV ) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are otherwise ineligible for ISIS Pharmaceuticals' controlled trials OR who have failed ISIS 2922 therapy on another controlled clinical trial.
PER 2/8/96 AMENDMENT: Patients must rollover from another ISIS 2922 controlled trial.
|Condition or disease||Intervention/treatment||Phase|
|Cytomegalovirus Retinitis HIV Infections||Drug: Fomivirsen sodium||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial)|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002356
Show 25 Study Locations